This article is more than 5 years old. Information may no longer be current.

Spark Therapeutics reports $123.7 million net loss in 2016

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Spark Therapeutics reported a net loss of $123.7 million, or $4.29 per share, in 2016 compared with a net loss of $47.8 million, or $2.10 per share, in 2015, according to a company press release.

Revenue in 2016 was $20.2 million, all from an agreement with Pfizer, compared with 2015 revenue of $22.1 million, of which $20.2 million was from the Pfizer agreement.

Research and development costs for the year were $86.4 million compared with $46 million in 2015. The difference was attributed to a $30.1 million increase in internal research and development expenses and a $10.3 million increase in external research and development.